{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"The relationship between PDL1 status and response to nivolumab will be explored. A Fisher's exact test will be used to assess the relationship between each biomarker and response to treatment. The power to detect the relationship of interest increases as the prevalence of the biomarker increases.","groups":[{"description":"Patients receive nivolumab IV over approximately 60 minutes once every 2 weeks for up to 46 doses in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nNivolumab: Given IV","id":"OG000","title":"Cohort A (Nivolumab - Closed to Accrual on 21-Oct-2015)"},{"description":"Patients receive nivolumab IV over approximately 60 minutes followed by a saline flush and ipilimumab IV over 90 minutes. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\nIpilimumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG001","title":"Cohort B (Nivolumab and Ipilimumab)"}],"populationDescription":"to few responders to analyze biomarker data","reportingStatus":"POSTED","timeFrame":"Up to 100 days","title":"PDL1 Status","type":"SECONDARY"}